آخرین مطالب

برخی از کارشناسان پزشکی اسرائیلی می گویند که چهارمین توصیه دوز واکسن کووید-19 به داده های بیشتری نیاز دارد


توصیه یک هیئت اسرائیلی برای تجویز چهارمین واکسن برای افراد بالای 60 سال با واکنش خفیف برخی از کارشناسان پزشکی این کشور مواجه شده است که معتقدند به داده های بیشتری نیاز است.

دکتر درور میوراچ، رئیس بخش ویروس کرونا در بیمارستان دانشگاه هداسا، عین کاره در اورشلیم، گفت: “من در ماه جولای از توصیه تقویت کننده حمایت کردم. اما آن زمان شواهد بهتری داشتیم. امروز، ما هیچ مدرک خوبی نداریم.”

“من فکر می کنم یک سوال بزرگ در مورد تاثیر این تقویت کننده چهارم وجود دارد. مطمئن نیستم که کمک کند.”

مووراخ به CBC News گفت که برخلاف تصمیم برای اجرای دوز سوم که با استقبال گسترده روبرو شد، این توصیه توسط برخی در جامعه پزشکی مورد سوال قرار گرفته است.

من می گویم که من ده ها تماس از پزشکان و دانشمندان دریافت کردم که به من گفتند که ما یکسان فکر می کنیم، هیچ مدرکی برای ارائه وجود ندارد. [a fourth dose} for the moment,” he said.

Israel’s PM welcomes recommendation

The recommendation for a fourth dose to people over 60, those with compromised immune systems and health-care workers was made based on concerns of waning immunity of the three vaccines already administered, combined with the potential threat of an Omicron outbreak seen in other countries.

“The price will be higher if we don’t vaccinate,” Boaz Lev, who heads the advisory committee, told reporters following the panel’s decision.

The recommendation was also welcomed by Israeli Prime Minister Naftali Bennett, who called it “great news that will help us overcome the Omicron wave that is spreading around the world.”

Israeli Prime Minister Naftali Bennett has welcomed the recommendation for a fourth vaccine dose. If approved, Israel would become the first country to roll out a fourth dose to some of its citizens. (Abir Sultan/Pool Photo/The Associated Press)

It is currently being reviewed by Israel’s director general of the Health Ministry, Nachman Ash. If approved, Israel would become the first country to roll out a fourth dose to some of its citizens. However there have been some reports that Ash might be stalling while he reviewed information from Britain that shows that Omicron leads to less severe illness than the Delta variant.

Dr. Ron Dagan, a professor of pediatrics and infectious diseases at the Ben-Gurion University of the Negev and a member of the expert panel, acknowledged that the recommendation was not based on data of fourth dose results “because there is no data.”

“There’s no data that we could base on our recommendation,” he told CBC News in a phone interview. “But on the other hand, there are data that altogether made us worried about what’s going on as a potential scenario in the upcoming weeks.”

There is evidence of waning immunity against infection about three to four months after the third vaccine was rolled out, he said.

‘Scientific evidence is not there’

Dagan said the panel didn’t believe a fourth shot would cause any harm, and it made an “educated guess” about Omicron’s potential impact and the benefits and risks of offering a fourth dose.

“To the best of our judgment, the potential benefits, we believe, are bigger than the potential risks.”

Mevorach said he respects the fact that some people believe that Israel is facing a potential catastrophe when it comes to Omicron and that they want to do everything they can.

A man is vaccinated at a shopping mall in Jerusalem on Wednesday as the COVID-19 vaccination campaign continues in Israel amid talks of a fourth dose for high-risk groups. (Ammar Awad/Reuters)

“But I must say that medical or scientific evidence is not there,” he said.

It may be better to wait for an Omicron specific booster, which both Pfizer-BioNTech and Moderna have indicated could be ready by March, he said.

Prof. Hagai Levine, an epidemiologist and chair of the Israel Association of Public Health Physicians, told the New York Times that while he respects the “better safe than sorry” opinion of the panel, “before giving a fourth shot, it is preferable to wait for the science.”

Nadav Davidovitch, director of the Ben-Gurion University School of Public Health, said he would have offered a “weaker recommendation” than what was put forward by the expert panel.

Instead of a “forceful campaign” for another booster, he said he would rather allow people that are high risk to choose to have the fourth dose, “because we don’t have enough data.”

Cyrille Cohen, head of the lab of immunotherapy at Bar-Ilan University, said he understands how the panel reached its conclusion and that it was all about “risk managing.”

“We see how [Omicron] در کشورهای دیگر در حال توسعه است و ما می ترسیم که در مقطعی موارد در اسرائیل منفجر شود.”

کوهن گفت: مشکل این است که ما داده های زیادی نداریم و این جایی است که فکر می کنم این چیز خوبی است که در حال حاضر کمی داده های بیشتری جمع آوری کنیم.

کوهن گفت که می‌خواهد روشن کند که فکر نمی‌کند به کسی بگوید که شلیک چهارم را نزند.

“من ترجیح می دهم بگویم، “خوب، ما به داده های بیشتری نیاز داریم.”